About this trial
Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardised documentation of this disease. The aim of the registry is to answer both epidemiological and therapy-specific questions.
This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form.
Eligibility criteria
Qualifiers
Histological evidence of breast cancer
Histological and/or radiological evidence of metastases
Metastasis within 10 years of registry initiation
Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)
Disqualifiers
Due to the non-interventional design of the registry there are no specific exclusion criteria.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Arbeitsgemeinschaft medikamentoese Tumortherapie
Lead sponsor
Hoffmann-La Roche
Collaborator
Daiichi Sankyo
Collaborator
Pfizer
Collaborator
Novartis
Collaborator
Caris Life Sciences
Collaborator
AstraZeneca
Collaborator
Seagen Inc.
Collaborator
Eli Lilly and Company
Collaborator